GenMark Diagnostics Reports Q3 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
October 28, 2015 11:02 AM EDTCanaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00), following the announcement of another delay on ePlex. GNMK cited their need to redesign plastic-injected parts to 2 components of their cartridge. GNMK pushed out its timelines by another quarter,... More
GenMark Diagnostics (GNMK) Pushes ePlex Launch to 2016; Needham & Company Cuts Price Target to $13
October 28, 2015 7:11 AM EDTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $13.00 (from $16.00), following the company's 3Q15 earnings results. Revenue was $8.5M vs. consensus of $8.2M and GAAP EPS was ($0.27) vs. consensus of ($0.31). Management now believes that the launch of the sample-to-answer... More
